Citations

Mayo Clinic

Clear

12 citation(s) found for "Allende, Daniela".

Enteroblastic and Hepatoid Colorectal Carcinomas are Aggressive Cancers With a Distinctive Immunophenotype, While Clear Cell Carcinoma Appears to Represent Clear Cell Change in Conventional Colorectal Cancer
Khan, Fahad, Polydorides, Alexandros D., Paulsen, John D., Chen, W, Vazzano, Jennifer , Huber, Aaron , Papke, David, Sharifai, Nima , Allende, Daniela, McHugh, Kelsey, Longacre, Teri A. , Dhall, Deepti, Makhoul, Elias, Lee, Michael J., Collins, Katrina, Ulbright, Thomas M. , Zhang, M. Lisa, Westerhoff, Maria , Gao, Zu‐Hua , Choi, Won‐Tak , Kakar, Sanjay, Chetty, Runjan, Nowak, Klaudia, Zhang, Xuchen, Chen, Wei , McHugh, Kelsey , Khan, Fahad , Gonzalez, Raul S , Chen, Wei , McHugh, Kelsey E , Polydorides, Alexandros D. , Paulsen, John David , Papke, David , Stashek, Kristen , Ruz‐Caracuel, Ignacio , Shia, Jinru , Dhall, Deepti , Collins, Katrina , Zhang, Mingjuan Lisa , Matsukuma, Karen , Kakar, Sanjay , Chetty, Runjan , Nowak, Klaudia M. , Serra, Stefano , González, Raul S.

American Journal of Surgical Pathology | April 21, 2026 | Volume: 50 | Issue: 8 | Pages: 883-893

10.1097/pas.0000000000002555 | PMID 42012857 Get It

Enteroblastic, hepatoid, and clear cell carcinomas are rare subtypes of colorectal carcinoma (CRC) with histologic and immunohistochemical (IHC) overlap. We assessed 37 CRCs that possibly represent these subtypes. Provisional criteria for each subtype, along with case photomicrographs and IHC data, were circulated among the authors to provide diagnostic interpretations. Based on plurality consensus, the carcinomas were classified as enteroblastic (n=13), hepatoid (n=6), and clear cell (n=18). Unanimous agreement was reached in 18% (3 clear cell, 3 hepatoid). Interobserver analysis revealed a mean pairwise Cohen κ of 0.63 (range: 0.32 to 0.91), with the hepatoid subtype eliciting the greatest consensus. Clear cell areas were the most likely to intermix with areas of conventional CRC ( P <0.001). Seven patients (20%) had inflammatory bowel disease (mostly linked to enteroblastic CRC). Twenty-three of 34 patients (68%) had nodal metastasis, and 12 (32%) had distant metastasis (mostly to the liver) at presentation. Median recurrence-free survival was 17 months, with enteroblastic cases the most likely to recur (54%, P =0.015). Median follow-up length was 27 months, with 14 patients (40%) dying of disease (representing 7 enteroblastic, 4 hepatoid, and 3 clear cell CRC). Mutations were identified in TP53 (n=8) , APC (n=3) , FBXW7 (n=2), and KRAS (n=1). Inflammatory bowel disease significantly worsened recurrence-free survival on multivariate analysis, while distant metastasis significantly worsened both recurrence-free and overall survival on multivariate analysis. Enteroblastic, hepatoid, and clear cell CRC demonstrate morphologic and IHC overlap, leading to interobserver variability in diagnosis. Given potential differences in clinical correlations and outcomes, more refined criteria are likely necessary.
Extrapancreatic Gastrointestinal Tract Grade 3 Well-Differentiated Neuroendocrine Tumors Behave Aggressively Compared With Lower-Grade Tumors Despite Similar Morphology
Vyas, Monika, Bellizzi, Andrew M., McHugh, Kelsey , Allende, Daniela, Shi, Chanjuan, Ma, Changqing , Shroff, Stuti G. , Cox, Brian , Padmanabha, Nandan , Gonzalez, Raul S , McHugh, Kelsey E , Bellizzi, Andrew M. , Singhi, Aatur Dilip , González, Raul S.

American Journal of Surgical Pathology | February 20, 2026 | Volume: 50 | Issue: 5 | Pages: 524-534

10.1097/pas.0000000000002514 | PMID 41717808 Get It

The WHO 2019 classification of digestive tract tumors introduced a high-grade (G3) category for well-differentiated neuroendocrine tumors (NETs). These neoplasms appear to have a better prognosis than poorly differentiated neuroendocrine carcinomas (NECs) and may not respond to platinum-based chemotherapy, which is the treatment of choice for NECs, justifying the creation of this new category. Most existing data on G3 NETs are derived from pancreatic neuroendocrine neoplasms, as the majority of G3 neuroendocrine neoplasms (NENs) arise there. G3 NETs are rare at extrapancreatic sites, and their prognosis and behavior are not well studied. We collected and analyzed a multi-institutional cohort of 24 extrapancreatic primary gastrointestinal G3 NETs based on mitotic rate and/or Ki67 index (5 gastric, 13 small bowel, 6 colorectal/anal). Mean Ki67 index was 29.3% (range: 10.5% to 50.2%). Cases generally showed typical well-differentiated NET morphology. Nodal metastases were present in 17/17 (100%) patients; 13/24 (45%) had distant metastases at initial presentation, and 7 patients developed them on follow-up. With a median of 29 months of follow-up, only 2 patients (8%) were alive without disease. Outcomes of G3 NETs were compared with a separate cohort of 125 extrapancreatic G1/G2 gastrointestinal NETs. G3 tumors presented at a higher pT-category stage ( P <0.001) and overall stage ( P =0.002), and patients with G3 disease were more likely to die than those with G1/G2 disease ( P <0.001). Our data show that, like pancreatic G3 NETs, rare extrapancreatic gastrointestinal G3 NETs exhibit aggressive behavior compared with their G1/G2 counterparts (although small bowel NETs tend to recur irrespective of grade). In most cases, the G3 designation is driven by Ki67 index, though exceptions exist, emphasizing the need for reviewing mitotic count in every case.
Hepatocellular adenomas with high-risk molecular alterations undetected by “high-risk” β-catenin and/or glutamine synthetase staining patterns
Gosnell, Hailey L. , Roberts, Daniel , Zhang, Xuefeng , Azzato, Elizabeth M. , Jacubowski, Maureen A, Toro, Paula , Corredor, Germán , Cheng, Yu‐Wei , Caldéraro, Julien , Kakar, Sanjay , Allende, Daniela , Cheng, Yu-Wei , Dermawan, Josephine K. , Graham, Rondell P. , Kakar, Sanjay

Am J Clin Pathol | November 14, 2025 | Volume: 164 | Issue: 6 | Pages: 908-916

10.1093/ajcp/aqaf115 | PMID 41236436 Get It

Abstract Objective β-Catenin–mutated hepatocellular adenomas (HCAs) carry an increased malignant transformation risk and are screened by interpreting glutamine synthetase (GS) and β-catenin by immunohistochemistry (IHC). Our study aims to assess GS and β-catenin interpretation guidelines for applicability and reproducibility in predicting high-risk HCA and other relevant molecular alterations. Methods Hematoxylin and eosin (H&E), β-catenin, GS, and CD34 stains from 75 HCAs were interpreted by three pathologists using Method A (GS interpretation: negative, perivenular patchy, map-like, diffuse, and indeterminate) and Method B criteria (similar GS interpretation scheme based on a recent publication, with and without CD34 expression patterns). Ease of application and interpretation confidence level were assessed. High-risk IHC was defined as nuclear β-catenin and/or diffuse homogeneous GS. Molecular testing was performed on a subset of HCAs and controls. Results There were 57 resections and 18 biopsy specimens examined. Methods A and B (GS only) were rated as easy to apply, with high interpretation confidence (≥90% using both methods). Consensus rate was comparable in biopsy specimens (100% for both methods) and resections (88% for Method A, 93% for Method B). While the same cases were stratified into high-risk GS categories using both systems, clinically significant genetic alterations (TERT promoter, EGFR, MTOR, and TP53) were identified in 25% of cases stratified as not high risk by IHC. Conclusions Both methods have a similar ease of application and level of interpretation confidence, and they also detected β-catenin mutations as expected. Other relevant molecular alterations associated with risk of neoplastic progression and/or bleeding were detected in 25% of HCAs with the non-high-risk IHC phenotype, suggesting the value of molecular testing in this subset.
Mucinous cystic neoplasm in men: a comparative study
Dundar, Bilge , Adsay, Volkan , Allende, Daniela , Jenkins, Sarah M. , Pai, Rish K. , Passow, Marie R. , Reid, Michelle D. , Westerhoff, Maria , Zen, Yoh , Graham, Rondell P. , Adsay, N Volkan , Allende, Daniela S , Graham, Rondell P , Reid, Michelle D

Histopathology | July 11, 2025 | Volume: 87 | Issue: 4 | Pages: 548-556

10.1111/his.15511 | PMID 40641220 Get It

AimsMucinous cystic neoplasms (MCN) are defined by the presence of an ovarian‐type stroma (OTS). Once ovarian stroma has become a requirement for the diagnosis of MCNs, studies using this criterion have disclosed that MCNs are seen almost exclusively (97%) in women. The occurrence of MCNs (with ovarian stroma) in men is exceedingly rare and raises questions about the origin of OTS and the role of hormones in tumourigenesis. This study aims to investigate the clinical and histopathological features of pancreatic or hepatic MCNs in men.Methods and resultsWe examined the MCN cases in men and compared them with age‐matched women. We further investigated MCN in premenopausal and postmenopausal women to explore the impact of hormonal status.The stromal cellularity tended to be lower in men as compared to women; however, limited numbers prevented statistical significance. Clinical presentation, tumour location, body mass index and cyst complexity were similar between men and age‐matched women, similarly in pre‐ and postmenopausal woman groups. All MCN cases, regardless of gender or hormonal status, showed OTS with positivity for oestrogen receptor (ER), androgen receptor (AR) and SF‐1 immunostains. Additionally, the presence of AR and ER‐beta in lining epithelial cells, in addition to the stromal cells, raised the probability for a potential role for local hormonal signalling in the pathogenesis of these tumours.ConclusionsMCNs in men had overlapping histopathologic and immunohistochemical profiles with those in women, regardless of menopausal status.
Colorectal adenosquamous carcinoma: clinicopathologic analysis of two large cohorts and literature review confirm poor prognosis and reveal prognostic aspects
González, Raul S. , Horton, Rachel K. , Zhang, Xuchen , Graham, Rondell P. , Longacre, Teri A. , Mehrotra, Anupamjit K., Allende, Daniela , McHugh, Kelsey , Shia, Jinru , Westerhoff, Maria , Chen, Wei , Vazzano, Jennifer , Cheema, Hassam, Ma, Changqing , Mannan, Abul Ala Syed Rifat , Agostini‐Vulaj, Diana , Kazemimood, Rossana , Henn, Patrick, Kakar, Sanjay , Choi, Won‐Tak , Adeyi, Oyedele , Allende, Daniela S , McHugh, Kelsey E , Srivastava, Amitabh , Chen, Wei , Vazzano, Jennifer , Swanson, Paul E , Ma, Changqing , Mannan, Abul A S R , Chetty, Runjan , Serra, Stefano , Agostini-Vulaj, Diana , Kazemimood, Rossana , Choi, Won-Tak , Adeyi, Oyedele , Jenkins, Sarah M. , Nagtegaal, Iris D , Gonzalez, Raul S , Graham, Rondell P , Srivastava, Amitabh , Chatterjee, Deyali , Nowak, Klaudia , Kakar, Sanjay , Jenkins, Sarah M, Nagtegaal, Irıs D.

Histopathology | January 31, 2025 | Volume: 86 | Issue: 7 | Pages: 1064-1081

10.1111/his.15412 | PMID 39887413 Get It

AimsWe compiled two cohorts of colorectal adenosquamous carcinoma (ASC) to describe its histologic and molecular aspects using modern parameters to compare them with literature reports using meta‐analysis of cohorts and individual case series.Methods and ResultsWe identified 53 colorectal ASC from 19 North American academic medical centres, in addition to national database reports on 94 Dutch cases. We analysed available clinical, histologic, and immunohistochemical features and patient outcome. ASC comprised 0.02% of colorectal cancers in the Dutch database. The median cohort patient ages at resection were 65 and 69 years (North American and Dutch cohorts, respectively), with a roughly equal male:female ratio. The squamous component represented between 5% and 95% of each tumour, with a median of 50%. Tumour‐infiltrating lymphocytes (TILs) were generally low (66%), and tumour budding was often Bd1 (64%). Most cases were pT3 (55%) or pT4 (40%), with nodal metastases in more than half (58%). Twenty‐three cases (43%) metastasized distantly, most commonly to the liver. Mismatch repair (MMR) deficiency was identified in 34% of the cases. Follow‐up was available for 48 patients; 13 (27%) had recurrent disease and 29 (60%) died. A total of 31 patients progressed, with median time to progression of 18 months. Available data for the Dutch cohort revealed largely similar findings, as did review of cases in the literature.ConclusionColorectal ASC usually presents at an advanced stage. Despite high rates of MMR deficiency and low tumour budding, TILs were generally low, and there is a high recurrence rate and poor prognosis.
Colorectal Carcinoma With Sarcomatoid Components
Golconda, Umamaheshwari, McHugh, Kelsey , Allende, Daniela , Collins, Katrina , Henn, Patrick, Lacambra, Maribel D. , Bejarano, P.A., Groisman, Gabriel M. , Zhang, Xuchen , McHugh, Kelsey E , Loughrey, Maurice Bernard , Monappa, Vidya , Hornick, Jason L. , González, Raul S.

American Journal of Surgical Pathology | December 29, 2023 | Volume: 48 | Issue: 4 | Pages: 465-474

10.1097/pas.0000000000002172 | PMID 38155543 Get It

Colorectal carcinoma with sarcomatoid components (which includes so-called carcinosarcomas and sarcomatoid carcinomas) is a rare subtype with 50 reported cases in the literature and overlapping criteria with undifferentiated carcinoma. We collected and described 15 cases from 10 men and 5 women, with a mean age of 66 years. Symptoms included abdominal pain and gastrointestinal bleeding. Most tumors presented in the rectosigmoid region, with a mean size of 8.2 cm. The sarcomatoid component, on average, represented 58% of the tumors and took many forms, including spindled (10 cases), anaplastic (9 cases), and rhabdoid (3 cases); one case showed osteoid matrix. Tumor budding was usually high, and tumor-infiltrating lymphocytes were usually low. The sarcomatoid component was keratin-positive in 10 cases. One case showed loss of mismatch repair protein expression, and 2 cases showed SMARCA4 loss (1 also with SMARCA2 loss). Molecular testing identified mutations in KRAS (n=1), NRAS (n=2), BRAF (n=2), APC (n=1), and TP53 (n=1) in a few cases. Tumors often presented at advanced stage, with 11 cases pT4, 9 cases with nodal metastases, and 7 cases with distant metastases. Follow-up was available for 10 cases (median: 2 months), with 2 alive without disease, 3 alive with disease, and 5 dead. Our findings roughly corresponded with those in previously reported cases. Colorectal carcinoma with sarcomatoid components is rare and aggressive, with a poor prognosis for many patients. We suggest that spindled cells, anaplasia, heterologous elements, and/or a component with definable sarcomatous lineage be used to distinguish colorectal carcinoma with sarcomatoid components from undifferentiated carcinoma.
Pathologic Examination of Pancreatic Specimens Resected for Treated Pancreatic Ductal Adenocarcinoma
Hosseini, Mojgan , Allende, Daniela , Esposito, Iréne , Shi, Jiaqi , Dhall, Deepti, Graham, Rondell P. , Baştürk, Olca , Hruban, Ralph H. , Klimstra, David S. , Adsay, Volkan , Society, for the Pancreatobiliary Pathology, Graham, Rondell P , Adsay, N Volkan , Wang, Huamin , Chetty, Runjan , Matsuda, Yoko , Deshpande, Vikram , Jang, Kee‐Taek , Kim, Grace , Luchini, Claudio , Reid, Michelle D. , Krasinskas, Alyssa M. , Society, for the Pancreatobiliary Pathology

American Journal of Surgical Pathology | December 10, 2021 | Volume: 46 | Issue: 6 | Pages: 754-764

10.1097/pas.0000000000001853 | PMID 34889852 Get It

Currently, there are no internationally accepted consensus guidelines for pathologic evaluation of posttherapy pancreatectomy specimens. The Neoadjuvant Therapy Working Group of Pancreatobiliary Pathology Society was formed in 2018 to review grossing protocols, literature, and major issues and to develop recommendations for pathologic evaluation of posttherapy pancreatectomy specimens. The working group generated the following recommendations: (1) Systematic and standardized grossing and sampling protocols should be adopted for pancreatectomy specimens for treated pancreatic ductal adenocarcinoma (PDAC). (2) Consecutive mapping sections along the largest gross tumor dimension are recommended to validate tumor size by histology as required by the College of American Pathologists (CAP) cancer protocol. (3) Tumor size of treated PDACs should be measured microscopically as the largest dimension of tumor outer limits that is bound by viable tumor cells, including intervening stroma. (4) The MD Anderson grading system for tumor response has a better correlation with prognosis and better interobserver concordance among pathologists than does the CAP system. (5) A case should not be classified as a complete response unless the entire pancreas, peripancreatic tissues, ampulla of Vater, common bile duct, and duodenum adjacent to the pancreas are submitted for microscopic examination. (6) Future studies on tumor response of lymph node metastases, molecular and/or immunohistochemical markers, as well as application of artificial intelligence in grading tumor response of treated PDAC are needed. In summary, systematic, standardized pathologic evaluation, accurate tumor size measurement, and reproducible tumor response grading to neoadjuvant therapy are needed for optimal patient care. The criteria and discussions provided here may provide guidance towards these goals.
Diagnostic challenges of focal nodular hyperplasia: interobserver variability, accuracy, and the utility of glutamine synthetase immunohistochemistry
Rowan, Daniel J. , Allende, Daniela , Liu, Xiuli , McKenzie, Catriona , Moreira, Roger K. , Mounajjed, Taofic, Said, Samar M. , Westerhoff, Maria , Jenkins, Sarah M. , Batts, Kenneth P. , Burgart, Lawrence J., Lamps, Laura W. , Graham, Rondell P. , Batts, Kenneth P , Graham, Rondell P , Bellizzi, Andrew M. , Gill, Ryan M.

Histopathology | June 3, 2021 | Volume: 79 | Issue: 5 | Pages: 791-800

10.1111/his.14424 | PMID 34080211 Get It

AimsThe diagnosis of focal nodular hyperplasia (FNH) and the interpretation of glutamine synthetase (GS) staining can be challenging on biopsies. We aimed to evaluate the reproducibility of needle biopsy diagnosis of FNH, the effect of GS immunohistochemistry on FNH diagnosis, and which histological features are most useful for the diagnosis of FNH.Methods and resultsThe study included virtual needle biopsies generated from 75 resection specimens (30 FNHs, 15 hepatocellular adenomas, 15 hepatocellular carcinomas, and 15 non‐lesional liver specimens). Pathologists were reasonably accurate (83.1%) in the diagnosis of FNH with haematoxylin and eosin alone. Ductular reaction and nodularity had the highest sensitivity for a diagnosis of FNH (88.1% and 82.2%, respectively), whereas central scar was the most specific feature (90.6%). The presence of two or more of the classic histological features had 89.6% sensitivity and 86.2% specificity for a diagnosis of FNH. Diagnostic accuracy was significantly higher with the addition of a GS stain. A map‐like GS staining pattern was highly specific (99.3%) for FNH. However, GS staining was interpreted as non‐map‐like in 14.4% of reviews of true FNH cases, and overall interobserver agreement for interpretation of the GS staining pattern was only moderate (kappa = 0.42).ConclusionsPathologists are reasonably accurate in the diagnosis of FNH on virtual biopsies, and GS staining improves accuracy. However, a subset of FNH cases remain challenging. Steatosis and a pseudo‐map‐like GS staining pattern were associated with increased difficulty. Therefore, although a map‐like GS staining pattern is useful for confirmation of a diagnosis, the lack of a map‐like GS staining pattern on needle biopsy does not necessarily exclude a diagnosis of FNH.
Molecular and Immunohistochemical Analysis of Mucinous Cystic Neoplasm of the Liver
Treeck, Benjamin J. Van , Lotfalla, Mira , Czeczok, Thomas , Mounajjed, Taofic, Moreira, Roger K. , Allende, Daniela , Naini, Bita V. , Westerhoff, Maria , Adsay, Volkan , Kerr, Sarah E. , IIyas, Sumera I, Smoot, Rory L. , Liu, Yuanhang , Davila, Jaime , Graham, Rondell P. , Van Treeck, Benjamin J, Czeczok, Thomas W, I Ilyas, Sumera, Smoot, Rory L , Graham, Rondell P , Davila, Jaime I , Adsay, N Volkan , Reid, Michelle D.

American Journal of Clinical Pathology | June 19, 2020 | Volume: 154 | Issue: 6 | Pages: 837-847

10.1093/ajcp/aqaa115 | PMID 32880620 Get It

Abstract Objectives Mucinous cystic neoplasm of the liver is characterized by neoplastic mucinous and/or biliary epithelium surrounded by ovarian-type stroma. Immunohistochemical studies have shown that the ovarian-type stroma expresses estrogen receptor, suggesting potential hormonal responsiveness. The molecular biology of mucinous cystic neoplasm of the liver remains poorly studied. Methods Transcriptome sequencing and immunohistochemistry were performed on a series of mucinous cystic neoplasms. Results Mucinous cystic neoplasm of the liver exhibited significantly increased RNA expression of ovarian stromal markers WT1, PR, and ER2 and sex cord stromal markers SF-1, inhibin-α, and calretinin compared with nonneoplastic liver. Immunohistochemistry confirmed the RNA-level data. Evidence for sex hormone biosynthesis was identified by significant overexpression of multiple estrogen biosynthetic enzymes. Expression of 17β-hydroxysteroid dehydrogenase 1 was confirmed immunohistochemically. Pathway analysis also identified significant upregulation of the hedgehog and Wnt pathways and significant downregulation of T-helper 1 and T-helper 2 pathways. Conclusions Mucinous cystic neoplasm of the liver recapitulates ovarian stroma at the morphologic, DNA, RNA, and protein levels. These data support the concept that this tumor likely arises from ectopic primitive gonadal tissue and/or stromal cells with capacity to transdifferentiate to ovarian cortical cells.
Transcriptomic and Proteomic Analysis of Steatohepatitic Hepatocellular Carcinoma Reveals Novel Distinct Biologic Features
Treeck, Benjamin J. Van , Mounajjed, Taofic, Moreira, Roger K. , Orujov, Mushfig , Allende, Daniela , Bellizzi, Andrew M. , Lagana, Stephen M. , Davila, Jaime , Jessen, Erik , Graham, Rondell P. , Van Treeck, Benjamin J, Davila, Jaime I, Graham, Rondell P , Bellizzi, Andrew M , Davila, Jaime I

American Journal of Clinical Pathology | June 19, 2020 | Volume: 155 | Issue: 1 | Pages: 87-96

10.1093/ajcp/aqaa114 | PMID 32885245 Get It

AbstractObjectivesSteatohepatitic hepatocellular carcinoma is a distinct variant of hepatocellular carcinoma strongly associated with underlying nonalcoholic steatohepatitis. The molecular biology of steatohepatitic hepatocellular carcinoma is not fully elucidated, and thus we aimed to investigate the molecular underpinnings of this entity.MethodsTranscriptomic analysis using RNAseq was performed on eight tumor-nonneoplastic pairs of steatohepatitic hepatocellular carcinoma with comparison to conventional hepatocellular carcinoma transcriptomes curated in The Cancer Genome Atlas. Immunohistochemistry was used to validate key RNA-level findings.ResultsSteatohepatitic hepatocellular carcinoma demonstrated a distinctive differential gene expression profile compared with The Cancer Genome Atlas curated conventional hepatocellular carcinomas (n = 360 cases), indicating the distinctive steatohepatitic hepatocellular carcinoma morphology is associated with a unique gene expression profile. Pathway analysis comparing tumor-nonneoplastic pairs revealed significant upregulation of the hedgehog pathway based on GLI1 overexpression and significant downregulation of carnitine palmitoyltransferase 2 transcript. Glutamine synthetase transcript was significantly upregulated, and fatty acid binding protein 1 transcript was significantly downregulated and immunohistochemically confirmed, indicating steatohepatitic hepatocellular carcinoma tumor cells display a zone 3 phenotype.ConclusionsSteatohepatitic hepatocellular carcinoma demonstrates a distinctive morphology and gene expression profile, phenotype of zone 3 hepatocytes, and activation of the hedgehog pathway and repression of carnitine palmitoyltransferase 2, which may be important in tumorigenesis.